Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
暂无分享,去创建一个
B. Cheson | R. Larson | F. Appelbaum | K. Rai | J. Kolitz | B. Peterson | L. Shepherd | C. Schiffer | C A Schiffer | F R Appelbaum | R A Larson | J Kolitz | B D Cheson | L Shepherd | K R Rai | B L Peterson | L Elias | J Hines | G A Threatte | L. Elias | J. Hines | G. Threatte
[1] K. Maloum,et al. Chlorambucil in Indolent Chronic Lymphocytic Leukemia , 1998 .
[2] M. Keating. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia. , 1993, Seminars in oncology.
[3] E. Estey,et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.
[4] M. Grever,et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. , 1988, Nouvelle revue francaise d'hematologie.
[5] E. Estey,et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.
[6] E. Cronkite,et al. Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.
[7] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[8] B. Barlogie,et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. , 1989, Blood.
[9] H. Kantarjian,et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Hiddemann,et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.
[12] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[13] M. Grever,et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group , 1988, American journal of hematology.
[14] E J Freireich,et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.
[15] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .